Recent advancements in tumor immunotherapy, particularly antibodies targeting CTLA-4 and PD-1/PD-L1, have effectively treated various cancers, including neuroendocrine tumors. This evidence concerns the gene CTLA4 and neuroendocrine neoplasm.